Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

Constantine S. Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Chan Yoon Cheah

Blood (2023) 142 (Supplement 1): 327.

https://doi.org/10.1182/blood-2023-179541

Published: 2023

Journal Articles

Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study

Alessandra Tedeschi, Chan Yoon Cheah, Stephen S. Opat, Emma Verner, Laura Magnano, Narendranath Epperla, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Mary Ann Anderson

Blood (2023) 142 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2023-178841

Published: 2023

Journal Articles

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data

Chan Y. Cheah, Constantine S. Tam, Masa Lasica, Emma Verner, Peter J. Browett, Mary Ann Anderson, James Hilger, Yiqian Fang, David Simpson, Stephen Opat

Blood (2022) 140 (Supplement 1): 2321–2323.

https://doi.org/10.1182/blood-2022-169662

Published: 2022

Journal Articles

Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

Blood (2022) 140 (Supplement 1): 6501–6503.

https://doi.org/10.1182/blood-2022-162135

Published: 2022

Journal Articles

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Jacob D. Soumerai, Masa Lasica, Stephen Opat, Chan Y. Cheah, Henry Chan, Emma Verner, Eva González Barca, Alessandra Tedeschi, James Hilger, Yiqian Fang, David Simpson, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 9325–9327.

https://doi.org/10.1182/blood-2022-169664

Published: 2022

Journal Articles

Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

Constantine S. Tam, Emma Verner, Masa Lasica, Alejandro Arbelaez, Peter J. Browett, Jacob D. Soumerai, James Hilger, Yiqian Fang, Jane Huang, David Simpson, Stephen Opat, Chan Yoon Y. Cheah

Blood (2021) 138 (Supplement 1): 1419.

https://doi.org/10.1182/blood-2021-148451

Published: 2021

Journal Articles

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Jan A. Burger, MD PhD, Tadeusz Robak, MDPhD, Fatih Demirkan, MD, Osnat Bairey, MD, Carol Moreno, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Talha Munir, MBBS, Don A. Stevens, MD, Sandra Dai, PhD MS, Leo W. K. Cheung, PhD, Kevin Kwei, PhD, Indu Lal, MD, Emily Hsu, PhD, Thomas J. Kipps, MD PhD, Alessandra Tedeschi, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134437

Published: 2020

Journal Articles

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Munoz, Alessandra Tedeschi, Andrew W. Roberts, John F. Seymour, Siminder Kaur Atwal, Yiling Yu, William Novotny, Eric Holmgren, Ziwen Tan, James D. Hilger, Jane Huang, Constantine S. Tam

Blood (2020) 136 (18): 2027–2037.

https://doi.org/10.1182/blood.2020006449

Published: 2020

Includes: Supplemental data

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Blood (2019) 134 (Supplement_1): 499.

https://doi.org/10.1182/blood-2019-125394

Published: 2019

Journal Articles

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Blood (2019) 134 (11): 851–859.

https://doi.org/10.1182/blood.2019001160

Published: 2019

Includes: Supplemental data

Journal Articles

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

Jorge J. Castillo, Gilad Itchaki, Jonas Paludo, Marzia Varettoni, Christian Buske, Toby A. Eyre, Julio C. Chavez, Kenneth H. Shain, Samar Issa, M. Lia Palomba, Oren Pasvolsky, David Simpson, Dipti Talaulikar, Constantine S. Tam, Alessandra Tedeschi, Stephen M. Ansell, Lakshmi Nayak, Steven P. Treon

Blood (2019) 133 (4): 299–305.

https://doi.org/10.1182/blood-2018-10-879593

Published: 2019

Journal Articles

Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma

David Simpson, MBChB, FRACP, FRCPA, Henry Chan, MBChB

Blood (2018) 132 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2018-99-110891

Published: 2018

Journal Articles

Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F)

Lauren Child, Henry Chan, MBChB, Ross Alistair Henderson, PhD MBChB, Anna Elinder, MBChB, Eileen Merriman, MBChB, Merit Hanna, MBChB, David Simpson, MBChB, FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 5220.

https://doi.org/10.1182/blood-2018-99-115993

Published: 2018

Journal Articles

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Devinder Gill, MD MRCP, FRCPath, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rosemary Anne Harrup, MD, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Oliver Giles Best, PhD BSc, Bryone Jean Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2018-99-114064

Published: 2018

Journal Articles

Bing Neel Syndrome: Retrospective Australasian Experience of a Rare Treatable Complication of Waldenström Macroglobulinaemia/ Lymphoplasmacytic Lymphoma

Dipti Talaulikar, PhD FRACP, FRCPA, MBBS, Tara Cochrane, MBBS, John Gibson, Nada Hamad, MBBS, BSc, MSc, Phoebe Joy Ho, MBBS DPhil FRACP FRCPA, Samar Issa, FRACP, Kwok Fiona, Jun Hee Lim, PhD, David Simpson, MBChB, FRACP, FRCPA, Constantine Tam, MD PhD, Jorge J. Castillo, MD

Blood (2018) 132 (Supplement 1): 5325.

https://doi.org/10.1182/blood-2018-99-113969

Published: 2018

Journal Articles

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Blood (2018) 132 (Supplement 1): 5565.

https://doi.org/10.1182/blood-2018-99-111369

Published: 2018

Journal Articles

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma

Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Michael Wang, MD, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Javier Munoz, MD, Tycel J. Phillips, MD, Won-Seog Kim, MD PhD, James Hilger, PhD, Jane Huang, MD, William Novotny, MD, Judith Trotman

Blood (2018) 132 (Supplement 1): 1592.

https://doi.org/10.1182/blood-2018-99-117224

Published: 2018

Journal Articles

Ibrutinib for the Treatment of Bing-Neel Syndrome

Gilad Itchaki, Jonas Paludo, MD, Maria Lia Palomba, MD, Marzia Varettoni, MD, Dipti Talaulikar, PhD FRACP, FRCPA, MBBS, Julio C. Chavez, MD, Christian Buske, MD, Alessandra Tedeschi, MD, David Simpson, MBChB, FRACP, FRCPA, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Samar Issa, FRACP, Stephen M. Ansell, MD PhD, Steven P Treon, MD PhD FRCP, Jorge J. Castillo, MD

Blood (2018) 132 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2018-99-116788

Published: 2018

Journal Articles

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Blood (2018) 132 (20): 2115–2124.

https://doi.org/10.1182/blood-2018-07-862334

Published: 2018

Includes: Supplemental data

NARROW

Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data

Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma

Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F)

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Bing Neel Syndrome: Retrospective Australasian Experience of a Rare Treatable Complication of Waldenström Macroglobulinaemia/ Lymphoplasmacytic Lymphoma

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma

Ibrutinib for the Treatment of Bing-Neel Syndrome

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only